Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation (ADAPT)
Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies
About this trial
This is an interventional treatment trial for Allogeneic Hematopoietic Stem Cell Transplantation focused on measuring Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell transplantation, AHSCT, Hematologic malignancies, Melphalan, Hematopoietic stem cell transplant -composite risk
Eligibility Criteria
Inclusion Criteria: Male or female aged 18-70 years Diagnosis of AML, ALL, MDS, MPN, CML, NHL, HD, CLL requiring AHSCT Has an HLA-matched related (MRD), HLA-matched unrelated (MUD), haploidentical (HAPLO) or 1-Ag mismatched unrelated donor (MMUD) Karnofsky performance >70% Adequate major organ system function as demonstrated by: Serum creatinine clearance equal or more than 50 ml/min (calculated with Cockroft-Gault formula). Bilirubin equal or less than 1.5 mg/dl except for Gilbert's disease. ALT or AST equal or less than 200 IU/ml for adults. Conjugated (direct) bilirubin less than 2x upper limit of normal. Left ventricular ejection fraction equal or greater than 40%. Diffusing capacity for carbon monoxide (DLCO) equal or greater than 50% predicted corrected for hemoglobin. Ability to understand and the willingness to sign a written informed consent. a. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, deaf, hard of hearing and illiterate individuals are eligible for this trial. Exclusion Criteria: Inability to comply with medical recommendations or follow-up Pregnancy Active/uncontrolled bacterial or viral infection (PI is the final arbiter of this criterion.) Has active CNS or ocular disease involvement within 3 months Patients with primary CNS lymphoma Patients who require modifications of the conditional regimen
Sites / Locations
- Chao Family Comprehensive Cancer Center, University of California IrvineRecruiting
Arms of the Study
Arm 1
Experimental
Patients with AML, ALL, MDS, MPN, CML, NHL, HD, CLL requiring AHSCT
Patients will be treated with allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on their Hematopoietic Cell Transplant - Composite Risk (HCT-CR), age, and Karnofski performance status (KPS).